Shailendra Singh, MD
Interventional Cardiology · Allentown, PANPI 1114213774
Payments from drug & device makers
Across 1,183 payments — averaging $765.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$317K
- Cathworks, Inc.$302K
- Johnson & Johnson$102K
- Boston Scientific$52K
- Chiesi USA, Inc.$44K
- Shockwave Medical, Inc$24K
- plus $65K from 26 others
What the payments were for
- Consulting fees$57,56712%
- Speaking & faculty fees$270,51958%
- Grants$1,1230%
- Travel & lodging$105,56222%
- Food & beverage$34,8447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 416 | $316,662 |
| Cathworks, Inc. | 95 | $302,293 |
| Johnson & Johnson | 122 | $101,757 |
| Boston Scientific | 169 | $52,367 |
| Chiesi USA, Inc. | 25 | $43,641 |
| Shockwave Medical, Inc | 57 | $23,964 |
| GE HealthCare | 16 | $22,438 |
| Penumbra, Inc. | 32 | $15,905 |
| Abiomed | 112 | $5,795 |
| Bard Peripheral Vascular, Inc. | 29 | $4,027 |
| Merit Medical Systems Inc | 4 | $3,392 |
| AstraZeneca | 11 | $2,763 |
| Terumo Medical Corporation | 18 | $2,380 |
| Angiodynamics, Inc. | 3 | $2,266 |
| Edwards Lifesciences | 13 | $2,007 |
| Abbott | 12 | $1,809 |
| Apollo Endosurgery US Inc | 6 | $495 |
| Esperion Therapeutics, Inc. | 6 | $411 |
| Philips North America LLC | 5 | $292 |
| Asahi Intecc USA, Inc. | 2 | $196 |
| Cardiovascular Systems Inc. | 4 | $184 |
| UCB, Inc. | 1 | $144 |
| Boehringer Ingelheim | 3 | $138 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $102 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| Surmodics, Inc. | 1 | $94 |
| Novartis | 3 | $85 |
| Inari Medical, Inc. | 4 | $61 |
| Saranas, Inc. | 1 | $40 |
| Pfizer | 2 | $27 |
| Tactile Systems Technology Inc | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$100,620
- FFRangio$52,569
- KENGREAL$33,442
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$23,081
- Ranger$22,356
- OEC$17,427
- ONYX FRONTIER$16,187
- RESOLUTE ONYX$14,940
- Indigo System$13,621
- CLEVIPREX$9,960
- SYMPLICITY G3$6,877
- GENERAL - THERAPIES$6,645
- COREVALVE EVOLUT R$5,698
- ROTAPRO$5,000
- ALLIA$4,199
- Impella$3,426
- Apollo ESG NXT System$2,291
- BRILINTA$2,263
- RotarexS 6 F x 135 cm$2,098
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,634
How this compares
$905,872 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $149,240 |
| XareltoRivaroxaban | 42 | $42,679 |
| Repatha SureclickEvolocumab | 44 | $37,736 |
| Praluent PenAlirocumab | 14 | $9,356 |
| Metoprolol Succinate | 230 | $3,897 |
| ClopidogrelClopidogrel Bisulfate | 168 | $2,572 |
| Rosuvastatin Calcium | 162 | $2,452 |
| Ezetimibe | 77 | $2,010 |
| Atorvastatin Calcium | 179 | $1,814 |
| Lisinopril | 110 | $778 |
| Metoprolol Tartrate | 89 | $662 |
| Losartan Potassium | 89 | $635 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 44 | $511 |
| Valsartan | 15 | $475 |
| Pravastatin Sodium | 19 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $27 | $149,240145 claims |
| Johnson & JohnsonXarelto | $101,757 | $42,67942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Allentown
- Nainesh PatelAllentown$1.1M
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Jay GiriPhiladelphia$1M
- James HarveyChambersburg$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.